Literature DB >> 6417026

Further purification and characterization of high-molecular-weight polysaccharide from Pseudomonas aeruginosa.

G B Pier, M Cohen, H Jennings.   

Abstract

Previously published reports on high-molecular-weight polysaccharides from immunotype 1 and 2 of Pseudomonas aeruginosa indicated the presence of high levels of mannose in these preparations. This mannose has been found to be due to the presence of a yeastlike mannan in high-molecular-weight polysaccharide preparations. The source of the mannan was found to be the tryptic soy broth used to grow the bacteria. Mannan could be removed from the polysaccharide preparations by chromatography over columns of concanavalin A-Sepharose. The resulting polysaccharides had the same serological reactivity against rabbit antisera and the same immunogenic properties in mice as did the mannan-containing polysaccharides. Comparison of mannan-depleted polysaccharide with preparations of high-molecular-weight polysaccharide obtained from either ultrafiltered tryptic soy broth or a chemically defined medium showed that these polysaccharides were immunologically and chemically similar. Human immune responses to mannan-depleted polysaccharide from the immunotype 1 strain of P. aeruginosa were comparable with those previously seen in humans receiving mannan-containing polysaccharides. Thus, we found that P. aeruginosa high-molecular-weight polysaccharides prepared in either tryptic soy broth and then subjected to concanavalin A-Sepharose chromatography, ultrafiltered tryptic soy broth, or a chemically defined medium were immunologically and chemically comparable.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6417026      PMCID: PMC264389          DOI: 10.1128/iai.42.3.936-941.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  STUDIES ON THE GRAM-NEGATIVE CELL WALL. I. EVIDENCE FOR THE ROLE OF 2-KETO- 3-DEOXYOCTONATE IN THE LIPOPOLYSACCHARIDE OF SALMONELLA TYPHIMURIUM.

Authors:  M J OSBORN
Journal:  Proc Natl Acad Sci U S A       Date:  1963-09       Impact factor: 11.205

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Growth of several cariogenic strains of oral streptococci in a chemically defined medium.

Authors:  B Terleckyj; N P Willett; G D Shockman
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

4.  Cross-protection by Pseudomonas aeruginosa polysaccharides.

Authors:  G B Pier
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

5.  Studies of lipopolysaccharides from Pseudomonas aeruginosa.

Authors:  S G Wilkinson; L Galbrath
Journal:  Eur J Biochem       Date:  1975-03-17

6.  Analytical characterization of lipopolysaccharide antigens from seven strains of Pseudomonas aeruginosa.

Authors:  D Horton; G Rodemeyer; T H Haskell
Journal:  Carbohydr Res       Date:  1977-05       Impact factor: 2.104

7.  Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

Authors:  G B Pier
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

8.  High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2.

Authors:  G B Pier; H F Sidberry; J C Sadoff
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

9.  Capsular polysaccharides and lipopolysaccharides from two Bacteroides fragilis reference strains: chemical and immunochemical characterization.

Authors:  D L Kasper; A Weintraub; A A Lindberg; J Lönngren
Journal:  J Bacteriol       Date:  1983-02       Impact factor: 3.490

10.  Enhanced detection with an enzyme-linked immunosorbent assay of candida mannan in antibody-containing serum after heat extraction.

Authors:  M A Lew; G R Siber; D M Donahue; F Maiorca
Journal:  J Infect Dis       Date:  1982-01       Impact factor: 5.226

View more
  8 in total

1.  Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; T McVeigh; P Owen
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

2.  Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.

Authors:  G B Pier; S E Bennett
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

3.  Smooth lipopolysaccharide is the major protective antigen for mice in the surface extract from IATS serotype 6 contributing to the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; R Lucken; P Owen
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

4.  Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa.

Authors:  G B Pier; M Pollack; M Cohen
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

5.  Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide.

Authors:  G B Pier; M Pollack
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

6.  Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.

Authors:  G B Pier; N L Koles; G Meluleni; K Hatano; M Pollack
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

7.  Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains.

Authors:  K Hatano; G B Pier
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

8.  Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.

Authors:  K Hatano; S Boisot; D DesJardins; D C Wright; J Brisker; G B Pier
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.